News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


PHARMAC disappointed drug promoted

22 December 2004

PHARMAC disappointed drug promoted despite potential side-effects

PHARMAC is calling for drug companies to act more swiftly when concerns are raised over potential side effects and to be responsible in the promotion of their drugs.

The call follows reports that show arthritis drug Celebrex, a Cox-2 Inhibitor, more than doubles the risk of heart attacks and strokes. The latest findings follow the international withdrawal two months ago of another Cox-2 Inhibitor Vioxx due to similar side effects.

PHARMAC Chief Executive Wayne McNee says it was disappointing that Pfizer continued to aggressively promote Celebrex to doctors despite the withdrawal of Vioxx and similar concerns being raised about its own drug.

“A United States study raised concerns about Celebrex, and as a result the Food and Drug Administration asked Pfizer to voluntarily withdraw its advertising. However, it is concerning that despite this request, Pfizer has said that it will continue to promote the product to doctors.

“It is difficult to comprehend how a company can justify continuing to promote the safety of these drugs, and to claim there is no increased risk of cardiovascular events.”

Wayne McNee says the safety concerns around these drugs have been known for at least four years. PHARMAC decided in January not to fund Cox-2 Inhibitors based on the evidence of potential risk to patients.

“Drug companies must take these concerns very seriously, and it is irresponsible for them to continue to promote the benefits of drugs and ignoring the potential risks.”

He says when making the funding decision PHARMAC concluded that there was no evidence the COX-2 Inhibitors worked better than the older medicines.

“This shows clearly that new is not always better. Patient safety is always an important part of our decision making and in this case there were clear question marks over the side effects of these drugs.”


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines

Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>

Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>


Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
Jenny Abrahamson's John & Charles Enys: Castle Hill Runholders, 1864-1891

This volume will be of interest to a range of readers interested in the South Island high country, New Zealand’s natural environment, and the history of science. More>>